Trevi Therapeutics (NASDAQ:TRVI) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report report published on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $7.00 price objective on the stock.

Several other brokerages also recently weighed in on TRVI. Needham & Company LLC reissued a buy rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Wednesday, May 8th. Oppenheimer restated an outperform rating and set a $9.00 price target on shares of Trevi Therapeutics in a research note on Thursday, March 21st.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $2.65 on Thursday. The stock has a market capitalization of $186.64 million, a P/E ratio of -7.79 and a beta of 0.87. The business has a fifty day moving average price of $2.74 and a 200 day moving average price of $2.29. Trevi Therapeutics has a 1-year low of $0.97 and a 1-year high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). As a group, equities research analysts anticipate that Trevi Therapeutics will post -0.42 earnings per share for the current fiscal year.

Insider Activity at Trevi Therapeutics

In related news, CEO Jennifer L. Good sold 25,037 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $2.86, for a total transaction of $71,605.82. Following the completion of the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at $610,075.18. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Trevi Therapeutics news, CEO Jennifer L. Good sold 25,037 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $2.86, for a total value of $71,605.82. Following the sale, the chief executive officer now owns 213,313 shares in the company, valued at approximately $610,075.18. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Thomas Sciascia sold 53,368 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $2.55, for a total transaction of $136,088.40. Following the sale, the insider now directly owns 214,433 shares in the company, valued at approximately $546,804.15. The disclosure for this sale can be found here. Insiders have sold a total of 87,333 shares of company stock worth $232,454 over the last quarter. Insiders own 24.37% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TRVI. Opaleye Management Inc. raised its holdings in Trevi Therapeutics by 48.6% in the 4th quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock worth $3,397,000 after purchasing an additional 829,100 shares during the period. Frazier Life Sciences Management L.P. lifted its position in shares of Trevi Therapeutics by 7.3% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock valued at $9,891,000 after buying an additional 500,000 shares in the last quarter. Propel Bio Management LLC acquired a new stake in Trevi Therapeutics in the 1st quarter valued at $897,000. SG Americas Securities LLC increased its holdings in Trevi Therapeutics by 401.4% in the 4th quarter. SG Americas Securities LLC now owns 98,253 shares of the company’s stock worth $132,000 after acquiring an additional 78,656 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new position in Trevi Therapeutics during the first quarter worth $208,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.